Novriana Dewi1, Peng Mi2,3,4, Hironobu Yanagie5,6,7, Yuriko Sakurai8, Yasuyuki Morishita9, Masashi Yanagawa10, Takayuki Nakagawa11, Atsuko Shinohara12, Takehisa Matsukawa13, Kazuhito Yokoyama13, Horacio Cabral14, Minoru Suzuki15, Yoshinori Sakurai15, Hiroki Tanaka15, Koji Ono15, Nobuhiro Nishiyama2,3, Kazunori Kataoka2,4,16, Hiroyuki Takahashi1,8. 1. Department of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. 2. Innovation Center of Nanomedicine, Kawasaki Institute of Industry Promotion, 66-20 Horikawa-cho, Saiwai-ku, Kawasaki, 212-0013, Japan. 3. Polymer Chemistry Division, Chemical Resources Laboratory, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta, Midori-ku, Yokohama, 226-8503, Japan. 4. Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. 5. Department of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. yanagie@my-pharm.ac.jp. 6. Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. yanagie@my-pharm.ac.jp. 7. Department of Innovative Cancer Therapeutics: Alpha Particle and Immunotherapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan. yanagie@my-pharm.ac.jp. 8. Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. 9. Department of Human and Molecular Pathology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 10. Department of Applied Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Nishi 2 Sen-11 Inadacho, Obihiro, Hokkaido, 080-0834, Japan. 11. Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. 12. Department of Humanities, Graduate School of Seisen University, 3-16-21 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8642, Japan. 13. Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. 14. Department of Bioengineering, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. 15. Research Reactor Institute, Kyoto University, Asahiro nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan. 16. Department of Materials Engineering, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Abstract
PURPOSE: A more immediate impact for therapeutic approaches of current clinical research efforts is of major interest, which might be obtained by developing a noninvasive radiation dose-escalation strategy, and neutron capture therapy represents one such novel approach. Furthermore, some recent researches on neutron capture therapy have focused on using gadolinium as an alternative or complementary for currently used boron, taking into account several advantages that gadolinium offers. Therefore, in this study, we carried out feasibility evaluation for both single and multiple injections of gadolinium-based MRI contrast agent incorporated in calcium phosphate nanoparticles as neutron capture therapy agent. METHODS: In vivo evaluation was performed on colon carcinoma Col-26 tumor-bearing mice irradiated at nuclear reactor facility of Kyoto University Research Reactor Institute with average neutron fluence of 1.8 × 10(12) n/cm(2). Antitumor effectivity was evaluated based on tumor growth suppression assessed until 27 days after neutron irradiation, followed by histopathological analysis on tumor slice. RESULTS: The experimental results showed that the tumor growth of irradiated mice injected beforehand with Gd-DTPA-incorporating calcium phosphate-based nanoparticles was suppressed up to four times higher compared to the non-treated group, supported by the results of histopathological analysis. CONCLUSION: The results of antitumor effectivity observed on tumor-bearing mice after neutron irradiation indicated possible effectivity of gadolinium-based neutron capture therapy treatment.
PURPOSE: A more immediate impact for therapeutic approaches of current clinical research efforts is of major interest, which might be obtained by developing a noninvasive radiation dose-escalation strategy, and neutron capture therapy represents one such novel approach. Furthermore, some recent researches on neutron capture therapy have focused on using gadolinium as an alternative or complementary for currently used boron, taking into account several advantages that gadolinium offers. Therefore, in this study, we carried out feasibility evaluation for both single and multiple injections of gadolinium-based MRI contrast agent incorporated in calcium phosphate nanoparticles as neutron capture therapy agent. METHODS: In vivo evaluation was performed on colon carcinoma Col-26 tumor-bearing mice irradiated at nuclear reactor facility of Kyoto University Research Reactor Institute with average neutron fluence of 1.8 × 10(12) n/cm(2). Antitumor effectivity was evaluated based on tumor growth suppression assessed until 27 days after neutron irradiation, followed by histopathological analysis on tumor slice. RESULTS: The experimental results showed that the tumor growth of irradiated mice injected beforehand with Gd-DTPA-incorporating calcium phosphate-based nanoparticles was suppressed up to four times higher compared to the non-treated group, supported by the results of histopathological analysis. CONCLUSION: The results of antitumor effectivity observed on tumor-bearing mice after neutron irradiation indicated possible effectivity of gadolinium-based neutron capture therapy treatment.
Authors: H Yanagië; T Tomita; H Kobayashi; Y Fujii; T Takahashi; K Hasumi; H Nariuchi; M Sekiguchi Journal: Br J Cancer Date: 1991-04 Impact factor: 7.640
Authors: Son Long Ho; Hyunsil Cha; In Taek Oh; Ki-Hye Jung; Mi Hyun Kim; Yong Jin Lee; Xu Miao; Tirusew Tegafaw; Mohammad Yaseen Ahmad; Kwon Seok Chae; Yongmin Chang; Gang Ho Lee Journal: RSC Adv Date: 2018-04-03 Impact factor: 4.036
Authors: Son Long Ho; Huan Yue; Tirusew Tegafaw; Mohammad Yaseen Ahmad; Shuwen Liu; Sung-Wook Nam; Yongmin Chang; Gang Ho Lee Journal: ACS Omega Date: 2022-01-12
Authors: Son Long Ho; Garam Choi; Huan Yue; Hee-Kyung Kim; Ki-Hye Jung; Ji Ae Park; Mi Hyun Kim; Yong Jin Lee; Jung Young Kim; Xu Miao; Mohammad Yaseen Ahmad; Shanti Marasini; Adibehalsadat Ghazanfari; Shuwen Liu; Kwon-Seok Chae; Yongmin Chang; Gang Ho Lee Journal: RSC Adv Date: 2020-01-03 Impact factor: 4.036